Low hygroscopic aripiprazole drug substance and processes...

Details Low hygroscopic aripiprazole drug substance and processes... Low hygroscopic aripiprazole drug substance and processes...

2011-03-22

2011-03-22

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S363000

Reexamination Certificate

active

07910589

ABSTRACT:
The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous aripiprazole crystals is stored for an extended period.

REFERENCES:
patent: 4734416 (1988-03-01), Banno et al.
patent: 4983607 (1991-01-01), Manoury et al.
patent: 5006528 (1991-04-01), Oshiro et al.
patent: 5073377 (1991-12-01), Alexander et al.
patent: 5162375 (1992-11-01), Nicholson et al.
patent: 5200410 (1993-04-01), Traber et al.
patent: 5385914 (1995-01-01), Fujioka et al.
patent: 5504093 (1996-04-01), Gelfand et al.
patent: 5652247 (1997-07-01), Ogawa et al.
patent: 5691330 (1997-11-01), Nakao et al.
patent: 5824680 (1998-10-01), Turner et al.
patent: 6267942 (2001-07-01), Mori et al.
patent: 7053092 (2006-05-01), Jordon et al.
patent: 2002/0076437 (2002-06-01), Kothari et al.
patent: 2003/0027817 (2003-02-01), Tollefson
patent: 2002226752 (2002-08-01), None
patent: 29 12 105 (1985-08-01), None
patent: 29 12 105 (1985-08-01), None
patent: 0 226 441 (1987-06-01), None
patent: 0 360 077 (1990-03-01), None
patent: 0 367 141 (1990-05-01), None
patent: 0 565 274 (1993-10-01), None
patent: 0 776 927 (1997-06-01), None
patent: 54-130587 (1979-10-01), None
patent: 2-191256 (1990-07-01), None
patent: A-70135 (1995-03-01), None
patent: 9-40648 (1997-02-01), None
patent: 11-508280 (1997-10-01), None
patent: 9-301 867 (1997-11-01), None
patent: 9-291034 (1997-11-01), None
patent: 11-509865 (1997-11-01), None
patent: 11-335286 (1999-12-01), None
patent: WO 92/10200 (1992-06-01), None
patent: WO 92/20655 (1992-11-01), None
patent: WO 93/04681 (1993-03-01), None
patent: WO 94/09765 (1994-05-01), None
patent: WO 94/13620 (1994-06-01), None
patent: WO 98/07426 (1998-02-01), None
patent: WO 98/08817 (1998-03-01), None
patent: WO 99/38864 (1999-08-01), None
patent: WO 02/102297 (2002-12-01), None
patent: 03/026659 (2003-04-01), None
patent: WO 03/026659 (2003-04-01), None
patent: WO 03/030868 (2003-04-01), None
Request for Re-examination of Australian Patent No. 2002226752 (Sep. 19, 2008).
Request for Re-examination of Australian Patent No. 2002334413 (Sep. 19, 2008).
Request for Re-examination of Australian Patent No. 2005201772 (Sep. 19, 2008).
Jing Kang Wang et al., The Effect of Physical Environment of Crystallization Process on the Polymorph of Cirprofloxacin Hydrochloride, School of Chemical Engineering and Technology, Tianjin University, Tianjin, 300072, P. R. China.
Wolfgang Beckmann, “Seeding the Desired Polymorph: Background, Possibilities, Limitations, and Case Studies, ” Chemical Engineering Department, Chemical Development, Schering AG, 13342 Berlin, Jul. 6 , 2000.
F. Puel et al., Polymorphism in Fine Organic Processes, LAGEP UMR CNRS 5007, Université Lyon 1 ESCPE. Bât. 308G, 43 Bd. du Nov. 11, 1918. F-69622 Villeurbanne, France.
Aoki at al.; “Study on Crystal Transformation of Aripiprazol”; 4thJapanese-Korean Symposium on Separation Technology, pp. 937-940, (1996).
Forbes et al.; “(R)-3,N-Dimethyl-N-[1-Methyl-3-(4-Methyl-Piperidin-1-YL)Propyl]Benzenesulfonamide: The First Selevtive 5-HT7Receptor Antagonist”; Journal of Medical Chemistry, vol. 41, No. 5, pp. 655-657, (1998).
Laurence M. Harwood et al., “Experimental Organic Chemistry Principles and Practice,” Blackwell Scientific Publications (1989), pp. 136-137.
Mino R. Caira, “Crystalline Polymorphism of Organic Compounds,” (1998), pp. 165-166.
Alan Rawla, “Basic Principles of Particle Size Analysis,” published by Malvern Instruments, pp. 1-8.
The United States Pharmacopeia (USP) 29, (2006), pp. 2788-2789.
Harry G. Brittain, “Spectral Methods for the Characterization of Polymorphs and Solvates,” Journal of Pharmaceutical Sciences, Apr. 1997, vol. 86, No. 4, pp. 405-412.
Kurt H. Bauer et al., “Pharmazeutische Technologie,” Georg Thieme Verlag, Stuttgart, (1986), pp. 75-81.
Harry G. Brittain, “Polymorphism in Pharmaceutical Solids,” New York (1999), pp. 334-335.
Notice of Opposition— Teva Pharmaceutical Industries Limited—Jan. 10, 2007.
Notice of Opposition—Fermion Oy—Jan. 11, 2007.
Notice of Opposition—Pharmaceutical Works POLYPHARMA—Jan. 16, 2007.
Notice of Opposition—EGIS Gyógyszergyár Nyrt—Jan. 15, 2007.
Notice of Opposition—ratiopharm GmbH—Jan. 15, 2007.
Y. Oshiro et al.; “Novel Antipsychotic Agents with Dopamine Autoreceptor Agonist Properties: Synthesis and Pharmacology of 7-[4-(4-Phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone Derivatives;” Journal of Med. Chemistry, vol. 41, No. 5, pp. 658-667, (1998).
The Merck Index—Aripiprazole, 2001.
Vippagunta, Sudha R. et al., “Crystalline Solids,” Advanced Drug Delivery Reviews 48 (2001) pp. 3-26.
Aulton, Michael E., Pharmaceutics: The Science of Dosage Form Design, Churchill Livingstone, Edinburgh, 1988, pp. 8-9 and 223-226.
Brittain, Harry G., Polymorphism in Pharmaceutical Solids, Marcel Dekker, Inc., New York, 1999, pp. 235-237 and 270-271.
Comparison of PXRD spectra; Hydrate A and MAB-1541-w—matching scales.
Comparison of PXRD spectra; Hydrate A and MAB-1541-w—spectra aligned to take account of systematic error.
European Medicines Agency report on aripiprazole, 2005.
European Patent Office Submission of EGIS GYÓGYSZERGYáR NYRT in Opposition to European Patent No. 1330249B1, Apr. 27, 2009.
European Patent Office Submission of Teva Pharmaceutical Industries Ltd. in Opposition to European Patent No. 1330249B1, Apr. 27, 2009.
Rhodes, Martin, Introduction to Particle Technology, John Wiley & Sons, Chichester, 1998, pp. 69-70.
Wade, Ainley & Weller, Paul J., Handbook of Pharmaceutical Excipients, American Pharmaceutical Association, Washington, and The Pharmaceutical Press, London, 1994, 2nd Ed., pp. 1-2.
Zakrzewski, Angeline & Marek, Solid State Characterization of Pharmaceuticals, 2006, pp. 134-135 and 152.
Affidavit of Professor Cools (2008), pp. 1-5.
Canive, J.M. et al., “Spontaneous Brain Magnetic Activity in Schizophrenia Patients Treated With Aripiprazole,” Psychopharmacol Bull. 1998;34(1):101-5.
Elvevag, B. et al., “Cognitive Impairment in Schizophrenia Is the Core of the Disorder,” Critical Reviews in Neurobiology 2000, 14(1), 1 to 21.
Inoue, A. et al., “Differential Effects on D2Dopamine Receptor and Prolactin Gene Expression by Haloperidol and Aripiprazole in the Rat Pituitary,” Molecular Brain Research 1998, 55, 285-292.
Kane, J.M. et al., “Efficacy of Aripiprazole in Psychotic Disorders: Comparison With Haloperidol and Placebo,” Int J Neuropsychopharmacol 2000 3; Suppl 1:Abst P01.124.
Keefe, R.S. et al., “The Effects of Atypical Antipsychotic Drugs on Neurocognitive Impairment in Schizophrenia: A Review and Metanalysis,” Schizophr Bull 1999:25:201-222.
Kern, R.S. et al., “An Open-label Comparison of the Neurocognitive Effects of Aripiprazole Versus Olanzapine in Patients With Stable Psychosis,” Schizophr Res 2001 49(1-2); Suppl S:234.
Mallikaarjun S et al., “The Pharmacokinetics, Tolerability, and Safety of Aripiprazole Following Single and Multiple Oral Dose Administration,” Int J. Neuropsychopharmacol 2000 3; Suppl 1:Abst P01.123.
Millan, M.J. et al., “Improving the Treatment of Schizophrenia: Focus on Serotonin (5-HT)(1A) Receptors,” J. Pharmacol. Exp. Ther. Dec. 2000; 295(3):853-61.
Mohs, R.C., “Cognition in Schizophrenia: Natural History, Assessment, and Clinical Importance,” Neuropsychopharmacology 1999, 21(6), pp. 203-210.
Petrie, J.L., “Acute and Long-Term Efficacy and Safety of Aripiprazole: A New Atypical Antipsychotic,” Schizophrenia Research 1998, 29 (1-2), 155.
Purdon, S.E., “Long-Term Treatment With Quetiapine Improves Cognitive Function in Schizophrenia,” Biol. Psych

Affiliated with

Also associated with

Rating

Low hygroscopic aripiprazole drug substance and processes... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Low hygroscopic aripiprazole drug substance and processes..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Low hygroscopic aripiprazole drug substance and processes... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2624200